image: This illustration shows the basic chemical structure of a prospective drug researchers are developing sitting inside the FLT3 target protein being tested as a possible new treatment for Acute Myeloid Leukemia. The scientists report in Science Translational Medicine the FLT3- inhibiting drug stops treatment-resistant AML in laboratory models of the disease. This material relates to a paper that appeared in the Sep. 5, 2019, issue of Science Translational Medicine, published by AAAS. The paper, by K. Melgar at Cincinnati Children's Hospital Medical Center in Cincinnati, OH; and colleagues was titled, "Overcoming adaptive therapy resistance in AML by targeting immune response pathways." view more
Credit: [Credit: Cincinnati Children's]